NCT03690141 2024-06-21
An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer
Effector Therapeutics
Phase 2 Terminated
Clinical Trials
4 trialsNCT02605083 2020-11-02
A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
Effector Therapeutics
Phase 1/2 Terminated
NCT02937675 2020-11-02
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
Effector Therapeutics
Phase 1/2 Terminated
NCT03318562 2019-07-18
A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
Effector Therapeutics
Phase 2 Terminated